关于瘤学中代理终点的常见问题 - - 机会,陷和前进的道路
Abhenil Mittal1, Myung Sun Kim2, Shenna Dunn3
1Department of Oncology, Northeast Cancer Center, Northern Ontario School of Medicine, Sudbury, ON, Canada.
EClinicalMedicine
|January 7, 2025
概括
癌症药物批准越来越依赖于替代终点,如瘤缩,而不是患者的生存或生活质量. 本审查审查了这些替代措施在瘤学中的有效性和过度使用.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 药物开发 药物开发
背景情况:
- 癌症药物批准往往优先考虑替代终点 (例如,瘤缩),而不是患者获益的直接措施,如整体存活率 (OS) 或生活质量 (QOL).
- 这些代用终点作为OS和QOL的代理值的有效性在不同癌症类型和治疗线上有很大差异.
- 人们越来越担心,替代终点在新癌症疗法的监管决策中可能过度使用.
研究的目的:
- 提供在瘤学临床试验中使用的代用终点的全面审查.
- 批判性地评估替代终点的定义,验证和可靠性.
- 解决有关癌症药物评估中代用终点的使用,益处和局限性的关键问题.
主要方法:
- 在治疗和晚期癌症环境中对代用终点的系统审查.
- 对代孕的验证方法和证据的分析.
- 预测与预后可靠性和监管要求的讨论.
- 问答格式解决了替代终点的常见问题.
主要成果:
- 替代终点通常与患者重要的结果 (OS,QOL) 存在较弱的相关性.
- 替代终点的实用性根据疾病背景和治疗线路不同.
- 对代用终点的监管依赖促进了更早的药物获取,但引起了对真正患者益处的担忧.
结论:
- 虽然替代终点为加速药物批准提供了潜在的好处,但它们与OS和QOL的弱相关性需要仔细验证和考虑.
- 过度依赖替代终点可能无法保证改善患者的治疗结果,这凸显了当前瘤学药物评估中的关键紧张局面.
- 提出了替代终点的未来使用和验证的框架建议,以更好地使药物批准与以患者为中心的目标保持一致.
相关概念视频
01:21Cancer Survival Analysis
289
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
289
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
101
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
101
01:24Kaplan-Meier Approach
51
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
51